Advertisement
Advertisement
U.S. markets close in 3 hours 32 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.5800+0.1900 (+7.95%)
As of 12:28PM EDT. Market open.
Advertisement

Chimerix, Inc.

2505 Meridian Parkway
Suite 100
Durham, NC 27713
United States
919 806 1074
https://www.chimerix.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees87

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael A. Sherman M.B.A.CEO, Pres & Director987.2kN/A1966
Mr. Michael T. Andriole M.B.A.Chief Bus. Officer, Sec. & CFO616.9kN/A1973
Dr. Allen S. Melemed M.B.A., M.D.Chief Medical Officer622.17kN/A1964
Mr. David Jakeman CPAExec. Director of Fin. & Accounting and Principal Accounting OfficerN/AN/A1978
Dr. Roy W. WareChief Manufacturing & Technology OfficerN/AN/AN/A
Dr. Randall LanierChief Science OfficerN/AN/AN/A
Ms. Michelle LaSpalutoVP of Strategic Planning & Investor RelationsN/AN/AN/A
Dr. Michael A. AlrutzSr. VP, Gen. Counsel & Corp. Sec.N/AN/A1970
Dr. Joshua E. AllenChief Technology Officer of ImipridonesN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Corporate Governance

Chimerix, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement